A Study of LY3437943 in Participants With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

Also called NCT04867785

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 281 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04867785
Other papers using this trial's data
  • Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial The lancet. Diabetes & endocrinology, 2025-08 DOI, PubMed 40609566
  • Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Lancet (London, England), 2023-08-12 DOI, PubMed 37385280

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04867785. Randomized; double masking; primary purpose treatment. Start 2021-05-13 (actual); primary completion 2022-07-08 (actual). Results posted on 2023-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3437943 in Participants With Type 2 Diabetes
Intervention (Drug)
LY3437943
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04867785
Content hash
9c2ecff95e7a165e64e74e83f10a74bca83f529b373db4db49472340051e1ccc